OPKO Health, Inc. (OPK)

US — Healthcare Sector

Peers: PSNL FLGT DMTKQ INO VXRT CODX IBIO

Automate Your Wheel Strategy on OPK

With Tiblio's Option Bot, you can configure your own wheel strategy including OPK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol OPK
Rev/Share 0.9207
Book/Share 1.7982
PB 0.7535
Debt/Equity 0.3051
CurrentRatio 3.4077
ROIC -0.0928

MktCap 1075575965.0
FreeCF/Share -0.3595
PFCF -4.1482
PE -5.5169
Debt/Assets 0.2006
DivYield 0
ROE -0.1318

Rating D+
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	OPK	JP Morgan	--	Neutral	--	--	April 25, 2025

News

OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands

OPK
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative

OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.

image for news OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

OPK
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative.

image for news OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

OPK
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Neutral

OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.

image for news Here's Why You Should Retain OPKO Health Stock in Your Portfolio

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

OPK
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral

Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.

image for news OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

OPK
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.

image for news OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

OPK
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive

OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

OPK
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

image for news OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates

OPK
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive

OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.

image for news OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates

About OPKO Health, Inc. (OPK)

IPO Date 1995-11-02
Website https://www.opko.com
Industry Medical - Diagnostics & Research
CEO Phillip Frost
Employees 2997

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.